论文部分内容阅读
目的探讨GP方案和TP方案对初治的晚期非小细胞肺癌的疗效和毒性。方法46例晚期非小细胞肺癌(ⅢB期30例,Ⅳ期16例)随机分成GP组和TP组,入组的每例患者接受至少2个周期以上的GP或TP同样方案的化疗,比较两组不同化疗方案的近期疗效和毒副作用。结果GP组和TP组的近期有效率分别为34.8%和39.1%,无统计学差异。毒副作用方面,GP组以血小板减少为主,TP组以白细胞减少为主,均在可耐受的范围内。结论GP和TP两种化疗方案对晚期非小细胞肺癌均有较好的临床疗效,化疗毒副作用虽有所不同,但均可耐受。因此,GP和TP两种化疗方案均可作为晚期非小细胞肺癌的一线治疗方案。
Objective To investigate the curative effect and toxicity of GP regimen and TP regimen on newly diagnosed advanced non-small cell lung cancer. Methods Forty-six patients with advanced non-small cell lung cancer (30 in stage ⅢB and 16 in stage Ⅳ) were randomly divided into GP group and TP group. Each patient enrolled in this study received at least 2 cycles of chemotherapy with the same regimen of GP or TP, Short-term efficacy and side effects of different chemotherapy regimens. Results The short-term effective rates of GP group and TP group were 34.8% and 39.1% respectively, with no significant difference. Toxic side effects, GP group thrombocytopenia, TP group mainly leukopenia, are within the tolerable range. Conclusion Both GP and TP chemotherapy regimens have good clinical efficacy in advanced non-small cell lung cancer. Chemotherapeutic toxicities and side effects may be different, but both are tolerable. Therefore, GP and TP two chemotherapy regimens can be used as a first-line treatment of advanced non-small cell lung cancer.